<DOC>
	<DOCNO>NCT00201877</DOCNO>
	<brief_summary>This study determine overall response rate toxicity rituximab Velcade combination patient relapse refractory mantle cell non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Velcade ( Bortezomib , PS-341 ) Rituximab Relapsed/Refractory Mantle Cell Follicular Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Rationale : Previous study test bortezomib rituximab separately indicate agent efficacy mantle cell lymphoma ( MCL ) . Bortezomib target cancer drug block proteasomes . The proteasome enzyme complex exist cell influence protein control cellular process . By block proteasome , bortezomib disrupts biologic pathway related growth survival cancer cell . Rituximab monoclonal antibody attache protein call CD20 antigen find almost exclusively surface B-cells leukemia . Once rituximab attache protein , immune system activates kill malignant B-cells . The current study combine bortezomib rituximab patient relapse refractory MCL . Purpose : This study evaluate safety efficacy bortezomib rituximab patient relapse refractory MCL . Blood , molecular , tumor analysis conduct provide researcher information area rituximab resistance , effect bortezomib cell associate immune function , protein alteration relate cellular growth death MCL . In addition , role maintenance therapy time administration MCL assess . Treatment : Patients study receive bortezomib rituximab . Both drug administer intravenous infusion . There two treatment period study . The first consider induction therapy patient receive bortezomib rituximab intermittently eighteen week period . Lower dosage rituximab give patient begin study ensure severe toxicity occurs . Those patient without disease growth eighteen week treatment continue maintenance therapy . During time period , patient give bortezomib rituximab one year half . Several test exams conduct throughout study closely monitor patient . Treatments discontinue due disease growth unacceptable side effect .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm mantle cell follicular lymphoma Relapsed refractory disease ECOG ( Eastern Cooperative Oncology Group ) performance status 0 , 1 , 2 3 Preexisting sensory motor peripheral neuropathy No active untreated CNS ( Central Nervous System ) lymphoma History severe , lifethreatening hypersensitivity infusion reaction prior rituximab treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Relapsed/Refractory</keyword>
	<keyword>NHL</keyword>
	<keyword>Follicular</keyword>
	<keyword>Mantle Cell</keyword>
	<keyword>non-Hodgkin 's lymphoma</keyword>
</DOC>